Cardioxyl Pharmaceuticals

Cardioxyl Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing innovative therapies for cardiovascular disease. The company is dedicated to discovering, developing, and commercializing novel technologies in areas where existing treatments are lacking or inadequate. With a strong emphasis on nitroxyl technology, Cardioxyl has established significant expertise in its chemistry, biology, and clinical applications. The company's leading candidate, CXL-1020, is currently undergoing clinical development for Acute Decompensated Heart Failure, a condition that is a primary cause of hospitalization among patients over the age of 65. Through its research and development efforts, Cardioxyl aims to address critical unmet needs in cardiovascular care.